Traded Apr 1 · filed 3 days later
Routine share withholding; mechanical by default.
Loading…
Traded Mar 16, 2026 · Filed Mar 18, 2026
The CEO of ADMA Biologics sold $227K of ADMA Biologics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$227,400
Shares × reported transaction price
19 days after results of Feb 25, 2026, 51 days before results of May 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −35.2% | −0.7% | −34.5% |
| 30 days | −26.0% | +7.4% | −33.3% |
| 90 days | −42.3% | +13.4% | −55.7% |
| 180 days | −38.5% | +15.0% | −53.6% |
Past results only. Not a forecast.
Traded Apr 1 · filed 3 days later
Routine share withholding; mechanical by default.
Traded Mar 13 · filed 5 days later
Derivative exercise or conversion — not an open-market buy.
Traded Mar 17 · filed 1 day later
Gift or transfer — classified separately from trades.